GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Cyclically Adjusted PB Ratio

MiMedx Group (MiMedx Group) Cyclically Adjusted PB Ratio : 10.28 (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Cyclically Adjusted PB Ratio?

As of today (2024-04-27), MiMedx Group's current share price is $6.27. MiMedx Group's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.61. MiMedx Group's Cyclically Adjusted PB Ratio for today is 10.28.

The historical rank and industry rank for MiMedx Group's Cyclically Adjusted PB Ratio or its related term are showing as below:

MDXG' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.6   Med: 10.62   Max: 33.43
Current: 10.27

During the past years, MiMedx Group's highest Cyclically Adjusted PB Ratio was 33.43. The lowest was 3.60. And the median was 10.62.

MDXG's Cyclically Adjusted PB Ratio is ranked worse than
90.17% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs MDXG: 10.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

MiMedx Group's adjusted book value per share data for the three months ended in Dec. 2023 was $0.976. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.61 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


MiMedx Group Cyclically Adjusted PB Ratio Historical Data

The historical data trend for MiMedx Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Cyclically Adjusted PB Ratio Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.53 14.76 9.58 4.42 14.42

MiMedx Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.42 5.46 10.73 11.97 14.42

Competitive Comparison of MiMedx Group's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, MiMedx Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Cyclically Adjusted PB Ratio falls into.



MiMedx Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MiMedx Group's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6.27/0.61
=10.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, MiMedx Group's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.976/129.4194*129.4194
=0.976

Current CPI (Dec. 2023) = 129.4194.

MiMedx Group Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.721 99.695 0.936
201406 0.707 100.560 0.910
201409 0.760 100.428 0.979
201412 0.829 99.070 1.083
201503 0.796 99.621 1.034
201506 0.856 100.684 1.100
201509 0.922 100.392 1.189
201512 1.006 99.792 1.305
201603 1.044 100.470 1.345
201606 1.105 101.688 1.406
201609 1.126 101.861 1.431
201612 1.211 101.863 1.539
201703 1.164 102.862 1.465
201706 1.310 103.349 1.640
201709 1.283 104.136 1.595
201712 0.665 104.011 0.827
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.455 105.998 0.556
201903 0.352 107.251 0.425
201906 0.221 108.070 0.265
201909 0.357 108.329 0.427
201912 0.310 108.420 0.370
202003 0.274 108.902 0.326
202006 0.207 108.767 0.246
202009 0.116 109.815 0.137
202012 -0.001 109.897 -0.001
202103 -0.072 111.754 -0.083
202106 -0.064 114.631 -0.072
202109 -0.052 115.734 -0.058
202112 0.001 117.630 0.001
202203 -0.066 121.301 -0.070
202206 -0.120 125.017 -0.124
202209 -0.172 125.227 -0.178
202212 -0.158 125.222 -0.163
202303 -0.156 127.348 -0.159
202306 -0.109 128.729 -0.110
202309 0.011 129.860 0.011
202312 0.976 129.419 0.976

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MiMedx Group  (NAS:MDXG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MiMedx Group Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604